A large number of medical representatives will be out

Pharmaceutical companies began to file yesterday, Saibai Blue in the China Chemical And Pharmaceutical Industry Association sponsored by the "pharmaceutical industry credit supervision and compliance management seminar" learned that many pharmaceutical companies have begun to carry out the filing of pharmaceutical representatives.
relevant pharmaceutical companies in carrying out this work at the same time, there are some questions, including, to the pharmaceutical representatives for the record of the field of drug treatment should be filled in? The representative of the co-operation CSO company, what kind of responsibility the industrial enterprises assume, etc.
On the above-mentioned issues, the relevant people responded that the pharmaceutical representative responsible for the treatment of products can be filled in according to the division of the national list of essential drugs, as for the cooperation of CSO's pharmaceutical representatives, still allow them to carry out academic promotion and other activities, but by the holder of its formal authorization, filing and management.
On the issue of pharmaceutical representatives filing responsibility subject, the above-mentioned person said that the pharmaceutical representative filing management measures a total of 17, the core concept is to adhere to the implementation of the main responsibility of the holder to the management of pharmaceutical representatives, which is in line with the provisions of the new version of the Drug Administration Law - drug market licensing holders for the entire process of drug management responsibilities.
In addition to the management measures for the record of pharmaceutical representatives, the credit evaluation system for pharmaceutical recruitment discussed at the same day's meeting is also designed to bind non-compliant acts such as commercial bribery of terminal promoters to upstream production enterprises, thus constraining the recruitment activities of listed license holders.
Not for the record, can not be promoted in the hospital Although at present, the pharmaceutical representative filing temporarily does not have a mandatory final registration time and publicity period, mainly depending on the specific work process of the listed license holder, but from December 1, 2020, medical institutions have the right to query the medical representative information according to the filing requirements or require the pharmaceutical representative to produce a filing form.
according to the regulations of the Administrative Measures, after December 1st, medical representatives who need to carry out academic promotion activities shall ensure that they have completed their filing with the filing platform designated by the State Administration.
In addition, medical institutions will also assume the following responsibilities, including: medical representatives to carry out academic promotion activities should be agreed to by medical institutions, the form of consent, content did not make specific requirements;
, with the gradual roll-out of the filing system for pharmaceutical representatives, pharmaceutical representatives who do not file will not be able to carry out academic promotion activities.
and complete the filing, it means that the name, gender, photo and other information of the pharmaceutical representative will be made public, plus the filing platform also provides the public-oriented drug filing information inquiry function, these medical representatives will be the follow-up to the hospital promotion will form considerable pressure.
it is worth noting that those who give medical personnel information transmission, academic promotion, adverse reactions to collect feedback are in the scope of the need for filing, not just limited to the enterprise identified pharmaceutical representatives this position.
that is, whether it is the Ministry of Medicine, the Marketing Department, or the Ministry of Government Affairs, if the relevant personnel engaged in the above-mentioned work, need to be filed.
threshold for pharmaceutical representatives will be raised According to the provisions of the record management measures, pharmaceutical representatives refer to professionals who, on behalf of drug listing license holders, are engaged in drug information transmission, communication and feedback within the territory of the People's Republic of China.
The main tasks of pharmaceutical representatives are: (1) to formulate plans and programs for the promotion of pharmaceutical products; (2) to convey relevant information on pharmaceutical products to medical personnel; (3) to assist medical personnel in the rational use of pharmaceutical products of the enterprise; and (4) to collect and feedback information on the clinical use of pharmaceutical products and hospital needs.
At the same time, the record management measures require that pharmaceutical representatives shall not engage in the following acts: (1) carry out academic promotion activities without the record; (2) carry out academic promotion activities without the consent of medical institutions; (3) undertake the task of drug sales, implement sales activities such as collection and processing purchase and sale bills; and (4) participate in the statistics of individual doctors the number of prescriptions for medicines; (5) providing donations, grants and sponsorships directly to departments and individuals in medical institutions; (6) misleading doctors about the use of drugs, exaggerating or misleading the efficacy, concealing information about known adverse reactions to drugs or concealing information on adverse reactions feedback from doctors; and (7) other interventions or acts affecting clinically reasonable drug use.
addition, drug market license holders shall strictly perform their administrative responsibilities to the pharmaceutical representatives employed or authorized, and it is strictly prohibited for pharmaceutical representatives to exist in such cases.
For pharmaceutical representatives who have the above-mentioned situations, the drug market license holder shall promptly correct them, and if the circumstances are serious, they shall suspend the authorization to carry out academic promotion and other activities, and train them in posts, and reconfirm the authorization after passing the examination.
According to Saibai Blue at the meeting learned that, although compared with the previous program, the formal implementation of the pharmaceutical representative record management method did not set the corresponding academic qualifications or professional access threshold for the pharmaceutical representative of the profession, but because the pharmaceutical representative filing management method actually raised the requirements for the pharmaceutical representative, and the management responsibility of the pharmaceutical representative to the drug market licensing, so the relevant pharmaceutical companies will have to gradually improve the recruitment of pharmaceutical representatives, which is also the relevant aspects of the development direction.
Cypress Blue learned at the meeting that the Chemical Drug Association is taking the lead in drafting the Code of Conduct for Pharmaceutical Representatives, which will soon be open to the industry for comments, will be how pharmaceutical representatives conduct business, how enterprises manage, regulate the representative team to conduct detailed norms.
Without academic promotion ability, will face the elimination of industry professionals pointed out that pharmaceutical representatives for the record management methods, pharmaceutical prices to recruit credit evaluation system, the establishment of pharmaceutical purchase and sale of the field of commercial bribery of bad records provisions, to correct the field of pharmaceutical purchase and sale and medical services in the wrong wind work points, local three must have and other policies are challenging the traditional drug promotion means of pharmaceutical representatives.
the new policy context, pharmaceutical representatives need to have at least four areas of knowledge: laws and regulations, industry norms and professional ethics education, medical and pharmaceutical related knowledge, product-related knowledge.
under this claim, still limited to the sale of gold, customer sales of pharmaceutical representatives, or will face elimination.
the relevant leadership of the State Drug Administration also said that with the implementation of the filing policy, the value of pharmaceutical representatives has been remodeled and adjusted, there is no academic ability of representatives are bound to face elimination, the future pharmaceutical representatives will play a more important role.
The prevailing view in the industry is that if pharmaceutical representatives really return to academic promotion, the only multinational pharmaceutical companies that can digest the employment of pharmaceutical representatives, as well as the few domestic innovative pharmaceutical enterprises and domestic pharmaceutical companies that are transforming and innovating - because only innovative drugs need real academic promotion.
In the long run, the value of pharmaceutical representatives will be reshaped and adjusted, and the pharmaceutical representatives responsible for the over-patented products, as well as all-round medicines with no clinical value, may disappear;
3 million medical representatives, can fully comply with the requirements of the filing system, responsible for the product can be very good academic promotion, how many?